Is BDTX or BLRX more undervalued in 2026?

CirclFi compares Black Diamond Therapeutics, Inc (BDTX) and BioLineRx Ltd. (BLRX) using 13 institutional-grade valuation models. BDTX has a Quality of Company score of 6.8/10 while BLRX scores 1.5/10.

Which is a better buy — BDTX or BLRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BDTX and BLRX valuations compare?

BDTX at $2.25 and BLRX at $3.59 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BDTX vs BLRX Valuation Comparison 2026 — Intrinsic Value Analysis

BDTX

Biotechnology

Black Diamond Therapeutics, Inc

Quality

6.8

out of 10

Value Trap

LOW

Price

$2.25

Last close

Models

10/13

Active

BLRX

Biotechnology

BioLineRx Ltd.

Quality

1.5

out of 10

Value Trap

SAFE

Price

$3.59

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	BDTX Fair Value	BDTX Upside	BLRX Fair Value	BLRX Upside
Bayesian DCF	Intrinsic	—	—	$0.95	-73.5%
Earnings Power Value	Intrinsic	$4.63	+64.1%	$1.00	-65.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.92	-45.8%	$1.50	-58.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BDTX vs BLRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BDTX vs BLRX — Which Stock Is More Undervalued?

BDTX scores higher with a 6.8/10 quality rating vs BLRX's 1.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Black Diamond Therapeutics, Inc (BDTX) and BioLineRx Ltd. (BLRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BDTX currently trades at $2.25 with a QOC of 6.8/10, while BLRX trades at $3.59 with a QOC of 1.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).